Today's Change
+0%
AI Sentiment
55%
Sector AnalysisLive data
Materials Sector Outlook
The Materials sector is up 0% today with neutral sentiment across 5 recent news articles.
Bullish Factors
- Predominantly positive news flow
Risk Factors
- No strong bearish signals detected
Stocks in Materials
0 stocks| Symbol | Company | Change |
|---|
Materials News
926 articles
GlobeNewswire Inc.86d ago
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - RGRD Law
GlobeNewswire Inc.86d ago
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm
GlobeNewswire Inc.86d ago
Bronstein, Gewirtz & Grossman LLC Urges Coty Inc. Investors to Act: Class Action Filed Alleging Investor Harm
The Motley Fool86d ago
Here's What to Expect for Gold and Silver Mining Stocks as the Iran Conflict Continues
GlobeNewswire Inc.86d ago
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
GlobeNewswire Inc.86d ago
ROSEN, A TOP-RANKED LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO
GlobeNewswire Inc.86d ago
ROSEN, A TRUSTED AND LEADING INVESTOR RIGHTS FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE
GlobeNewswire Inc.87d ago
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
GlobeNewswire Inc.87d ago
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
GlobeNewswire Inc.87d ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
GlobeNewswire Inc.87d ago
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Market Sentiment
Neutral
55% Sentiment Score
Sector Stats
Total Stocks0
News Today5
Avg Volume0
AI SentimentNeutral